Public-plan records, documented services and the questions the available sources cannot settle.
What this page answers
Semaglutide for diabetes on the public plan: Special Authorization (diabetes) for Ozempic and generics.
Weight-management products on the public plan: No weight product found.
Services documented as offered in Newfoundland and Labrador: 2 of 7 checked, on the companies' own pages.
Public care route: not researched for this record.
Evidence depth: moderateDepth describes the research scope, not coverage and not clinical quality.
Public coverage record
Evidence depth: moderateModerate: generic listings and diabetes criteria were read from opened documents; some fields (for example interchangeability) are unknown.
Public plan record for Newfoundland and Labrador, as read from the documents named below
Semaglutide for type 2 diabetes (public plan)
Special Authorization (diabetes) for Ozempic and generics; criteria: T2D with metformin after inadequate control, or documented metformin intolerance; 1 mg weekly ceiling
Weight-management products (public plan)
No weight product found
Imcivree for rare genetic obesity
not found in sources checked
Generic interchangeability with Ozempic
criteria say Ozempic and generics; DINs not enumerated
Source document date
Criteria PDF updated 2026-08-12 (Ozempic section July 2026, Rybelsus section May 2026)
A listing is not a decision about an individual claim. Criteria, special authorization and the plan's own process still apply.
Services that mention Newfoundland and Labrador
Seven services were checked. Each record is what the company's own pages said on the access date.
Documented matches, in alphabetical order
The company's own page names this jurisdiction for its weight service on the access date. Company self-report is not a licence check and not a quality signal.
Weight page FAQ says all Canadian provinces. Territories not named. Wording is a blanket statement, not a province-by-province list; keep the label company self-report. R22-C91R41-C51R41-C52
Recorded state, as written in the data
company self-report: offered
Operator
Hims & Hers Canada Inc.
Initial care fee, as displayed
Free in English and French browser views; $99 still in extracted text of both
Recurring care fee, as displayed
Weight-specific fee unknown
Source undated (live page and text extraction differed on consult fee)Accessed 2026-09-23
These records are conflicting, not found in the sources checked, explicitly not offered, not applicable or not researched. They are never mixed in with matches.
Doctor/NP assessment, ongoing reviews and renewals
Conflicting
Three Maple pages disagree. Help page (17 Apr 2026): all locations except NS, NU, NT. Assessment landing page: AB, BC, MB, NB, NL, ON, PEI, QC, SK, Yukon. Obesity page: complimentary assessment in Ontario only. Only ON appears on all three. Display as a dated conflict. R22-C32R22-C33A-C34R41-C19R41-C20R41-C21
Recorded state, as written in the data
conflicting (help page and assessment page name it; obesity page says Ontario only)
Operator
Maple Corporation
Initial care fee, as displayed
Covered by membership (help page); Ontario only per obesity page (conflicting)
Recurring care fee, as displayed
General membership $85/month outside QC; $95/month QC
Referral to specialist; groups and continuing physician support
Not applicable
MSP-covered program for BC residents, virtual or clinic visits, physician referral required. No other province named on checked pages; a BC MSP program is not applicable outside BC. R22-C71R22-C72B-C14aR41-C68
Recorded state, as written in the data
not applicable (BC MSP program)
Operator
Legal operator not found; OMDI/Medical Weight Management branding
No weight-service province or territory list found on the three checked pages. Partner pharmacy is an Ontario corporation (ScaleRx), which does not establish prescribing reach. R22-C98R22-C102R41-C75R41-C76R41-C77
Recorded state, as written in the data
not found in sources checked
Operator
Jack and Jill Health Inc.
Initial care fee, as displayed
$0 initial fee (waived), then $59/month; not a free first month
No weight-specific province list found. Platform terms exclude Quebec and describe pharmacy delivery to provinces and territories; delivery reach is not prescribing reach. Pharmacy operators are in BC and ON. R22-C105R22-C106R22-C111R41-C86R41-C87R41-C88
Weight service list is six provinces. The general platform list adds NS and NL for other categories only; treat NS and NL as explicitly not offered for weight. Territories and QC, NB not named on either list. R22-C02R22-C04R41-C01R41-C02
Recorded state, as written in the data
explicitly not offered for weight (named for other categories only)
Operator
Felix Inc.; Felix Health Inc. also appears
Initial care fee, as displayed
Main free; funnel $99
Recurring care fee, as displayed
$40 follow-up
Source 2026-09-16 (page said updated yesterday on 2026-09-17)Accessed 2026-09-23
Next research step recorded for this jurisdiction: none scheduled; monthly recheck. Recheck assumption: every 30 days for coverage and every 7 days for service pages.
Company self-report: offeredThe company's own page says it offers the service there. This is not a check of licensing or quality.
ConflictingTwo or more of the company's own pages disagree. Both values are shown with their dates.
Not found in sources checkedThe researcher looked and did not find it. This is not the same as not offered.
Explicitly not offeredThe company's page says it does not serve that place.
Not applicableThe service is a public program limited to one province by design.
Not researchedNobody has looked yet.
Sources for this page
Every claim ID below is a row in the evidence ledger. The source date is the date the source itself carries; the access date is when the researcher opened it. A claim with several rows is one claim with several sources, not several confirmations.
This table scrolls sideways.
Source records for every claim cited on this page
Claim
What the source says
Source
Source date
Accessed
Label
A-C29
NL SA portal links current criteria dated August 12, 2026
NL SA landing page links an August2026 criteria PDF described as updated August12 2026; Ozempic section within is updated July2026 and Rybelsus section May2026.
NL Ozempic criteria explicitly include generics; injectable semaglutide for T2DM with metformin after inadequate control on diet/exercise/metformin, or documented metformin contraindication/intolerance. Entry updated July2026.
August 2026; Ozempic entry updated July 2026; Rybelsus entry updated May 2026
2026-09-17
regulator-confirmed
R21-C534
NL T2DM-only coverage allows at most one agent among DPP-4 inhibitors, SGLT2 inhibitors and GLP-1 agonists and does not fund concurrent oral/injectable semaglutide; injectable semaglutide reimbursement maximum1mg onceweekly.
August 2026; Ozempic entry updated July 2026; Rybelsus entry updated May 2026
2026-09-17
regulator-confirmed
R21-C535
NL Rybelsus3,7,14mg tablet SA entry updated May2026 is for T2DM with metformin after inadequate control and includes the same combination restrictions.
